1.This test is designed for the detection of RET gene rearrangement status in human non-small cell lung cancer.
2.RET rearrangements occur in 1%-2% of non-small cell lung adenocarcinoma cases. This genetic alteration guides the use of targeted drugs including Vandetanib and Sorafenib.